Table of Content


Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing this Study
1.3 Scope of Report
1.4 Information Sources
1.5 Methodology
1.6 Geographic Breakdown
1.7 Analyst’s Credentials

Chapter 2 Summary and Highlights

Chapter 3 Market Overview
3.1 Nasal Immune Response
3.2 Benefits of Developing Nasal Vaccines
3.3 Market Drivers
3.3.1 Rising Incidence of Respiratory Infections
3.3.2 Cost-Effective Alternative to Mainstream Vaccines
3.3.3 Increased Government Support and Favorable Regulations
3.3.4 Rising Awareness of the Need for Vaccination Programs
3.3.5 R&D for Nasal Vaccines
3.4 Market Restraints
3.4.1 Limited Immunization in Low- and Middle-Income Countries
3.4.2 Technical Drawbacks of Nasal Vaccines
3.5 Market Opportunities
3.5.1 Demand for Innovative Approaches to Combat COVID-19
3.6 PESTEL Analysis
3.7 Reimbursement Scenarios
3.8 Impact of COVID-19 on the Market for Nasal Vaccines

Chapter 4 Pipeline Analysis of Nasal Vaccines
4.1 Nasal Vaccine Product Pipeline
4.1.1 Product Pipeline, by Clinical Trial Phase
4.1.2 Product Pipeline, by Disease
4.1.3 Product Pipeline, by Vaccine Type

Chapter 5 Global Market for Nasal Vaccines by Type
5.1 Live-Attenuated Vaccines
5.2 Inactivated Vaccines
5.3 Viral Vector Vaccines
5.4 Protein Subunit Vaccines

Chapter 6 Global Market for Nasal Vaccines by Dosage Form
6.1 Nasal Sprays
6.2 Nasal Drops
6.3 Nasal Powders
6.4 Nasal Gels

Chapter 7 Global Market for Nasal Vaccines by Patient Group
7.1 Pediatric
7.2 Adult

Chapter 8 Global Market for Nasal Vaccines by End User
8.1 Primary Care Clinics
8.2 Hospitals
8.3 Pharmacies
8.4 Other End Users

Chapter 9 Global Market for Nasal Vaccines by Region
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Rest of the World (RoW)

Chapter 10 Competitive Landscape
10.1 Announcements
10.2 Drug Approvals
10.3 Partnerships and Collaborations

Chapter 11 Company Profiles
ASTRAZENECA PLC
BHARAT BIOTECH INTERNATIONAL LTD.
BIODIEM LTD.
BLUEWILLOW BIOLOGICS INC.
CODAGENIX INC.
CHANGCHUN BCHT BIOTECHNOLOGY CO.
CYANVAC LLC
INTRAVACC LLC
MEISSA VACCINES INC.
RAZI VACCINE AND SERUM RESEARCH INSTITUTE
SERUM INSTITUTE OF INDIA PVT. LTD.



List of Figures



Summary Figure A : Global Market for Nasal Vaccines, by Region, 2022 and 2027
Summary Figure B : Pipeline Analysis of Nasal Vaccines, by Clinical Trial Phase, 2019–2022
Figure 1 : PESTEL Analysis of the Nasal Vaccine Market
Figure 2 : Distribution Share of Nasal Vaccine Product Pipeline, by Clinical Trial Phase, 2019–2022
Figure 3 : Distribution Share of Nasal Vaccine Product Pipeline, by Disease, 2019–2022
Figure 4 : Distribution Share of Nasal Vaccine Product Pipeline, by Vaccine Type, 2019–2022
Figure 5 : Global Market Shares of Live-Attenuated Nasal Vaccines, by Region, 2022
Figure 6 : Global Market for Live-Attenuated Nasal Vaccines, 2019–2027
Figure 7 : Global Market Shares of Nasal Spray Vaccines, by Region, 2022 and 2027
Figure 8 : Global Market Shares of Nasal Vaccines, by Patient Group, 2022
Figure 9 : Global Market for Nasal Vaccines, by End User, 2022 and 2027
Figure 10 : Snapshot of the Global Market Shares of Nasal Vaccines, by Region, 2022
Figure 11 : North American Market for Nasal Vaccines, 2019–2027
Figure 12 : European Market for Nasal Vaccines, 2019–2027
Figure 13 : Asia-Pacific Market for Nasal Vaccines, 2019–2027
Figure 14 : Rest of the World Market for Nasal Vaccines, 2019–2027
Figure 15 : Global Market Shares of Nasal Vaccines, by Key Strategies Adopted, 2020–2022
Figure 16 : AstraZeneca: Annual Revenue, 2019–2021
Figure 17 : AstraZeneca: Total Sales Share, by Segment, 2021
Figure 18 : AstraZeneca: Total Revenue Share, by Region, 2021

List of Tables



Summary Table : Global Market for Nasal Vaccines, by Region, Through 2027
Table 1 : Impact Analysis of Market Drivers and Restraints
Table 2 : Confirmed Cases of COVID-19, by Region, as of September 27, 2022
Table 3 : Global Nasal Vaccine Product Pipeline, 2019–2022
Table 4 : Global Market for Live-Attenuated Nasal Vaccines, by Region, Through 2027
Table 5 : Global Market for Nasal Spray Vaccines, by Region, Through 2027
Table 6 : Global Market for Nasal Vaccines, by Patient Group, Through 2027
Table 7 : Global Market for Pediatric Nasal Vaccines, by Region, Through 2027
Table 8 : Global Market for Adult Nasal Vaccines, by Region, Through 2027
Table 9 : Global Market for Nasal Vaccines, by End User, Through 2027
Table 10 : Global Market for Nasal Vaccines in Primary Care Clinics, by Region, Through 2027
Table 11 : Global Market for Nasal Vaccines in Hospitals, by Region, Through 2027
Table 12 : Global Market for Nasal Vaccines in Pharmacies, by Region, Through 2027
Table 13 : Global Market for Nasal Vaccines for Other End Users, by Region, Through 2027
Table 14 : North American Market for Nasal Vaccines, by Patient Group, Through 2027
Table 15 : North American Market for Nasal Vaccines, by End User, Through 2027
Table 16 : European Market for Nasal Vaccines, by Patient Group, Through 2027
Table 17 : European Market for Nasal Vaccines, by End User, Through 2027
Table 18 : Asia-Pacific Market for Nasal Vaccines, by Patient Group, Through 2027
Table 19 : Asia-Pacific Market for Nasal Vaccines, by End User, Through 2027
Table 20 : Rest of the World Market for Nasal Vaccines, by Patient Group, Through 2027
Table 21 : Rest of the World Market for Nasal Vaccines, by End User, Through 2027
Table 22 : Announcements in the Global Nasal Vaccines Market, 2020–2022
Table 23 : Recent Drug Approvals in the Global Nasal Vaccines Market, 2021–2022
Table 24 : Partnerships and Collaborations in the Global Nasal Vaccines Market, 2020–2021
Table 25 : AstraZeneca: Vaccine Portfolio
Table 26 : AstraZeneca: Financial Performance, 2019-2021
Table 27 : AstraZeneca: Recent Developments, 2022
Table 28 : Bharat Biotech: Vaccine Portfolio
Table 29 : Bharat Biotech: Recent Developments, 2022
Table 30 : BioDiem Ltd.: Vaccine Portfolio
Table 31 : BioDiem Ltd.: Financial Performance, 2019–2021
Table 32 : BioDiem Ltd.: Recent Developments, 2020–2021
Table 33 : BlueWillow Biologics Inc.: Vaccine Development Programs
Table 34 : BlueWillow Biologics Inc.: Recent Developments, 2019–2022
Table 35 : Codagenix Inc.: Vaccine Portfolio
Table 36 : Codagenix Inc.: Recent Developments, 2020–2022
Table 37 : BCHT: Vaccine Portfolio
Table 38 : BCHT: Recent Developments, 2021
Table 39 : CyanVac LLC: Vaccine Portfolio
Table 40 : CyanVac LLC: Recent Developments, 2021–2022
Table 41 : Intravacc LLC: Vaccine Portfolio
Table 42 : Intravacc LLC: Financial Performance, 2019–2021
Table 43 : Intravacc: Recent Developments, 2022
Table 44 : Meissa Vaccines Inc.: Vaccine Portfolio
Table 45 : Meissa Vaccines Inc.: Recent Developments, 2020–2022
Table 46 : Razi Vaccines: Vaccine Portfolio
Table 47 : Razi Vaccines: Recent Developments, 2021
Table 48 : Serum Institute of India: Vaccine Portfolio
Table 49 : Serum Institute of India: Recent Developments, 2020–2021